627536-09-8

SD-208是一种选择性TGF-βRI (ALK5)抑制剂，with IC50为48 nM，选择性比TGF-βRII高100多倍。

SD-208 inhibits the cell growth and constitutive and TGF-beta-evoked migration and invasion, and enhances immunogenicity in murine SMA-560 and human LN-308 glioma cells. SD-208 blocka TGF-beta-induced phosphorylation of the receptor-associated Smads, Smad2 and Smad3, and stimulates epithelial-to-mesenchymal transdifferentiation, migration, and invasiveness into Matrigel in vitro. SD-208 also abolishes the promoting effect of TGF-β on neointimal smooth muscle-like cell (SMLC) proliferation and migration in vitro.

SD-208 (1 mg/mL, p.o.) significantly prolongs the median survival of SMA-560 glioma-bearing mice. In syngeneic 129S1 mice, SD-208 (60 mg/kg/d, p.o.) inhibits primary R3T tumor growth, and reduces the number and the size of lung metastases. In the murine aortic allograft model, SD-208 effectively reduces the formation of intimal hyperplasia of transplant arteriosclerosis (TA).

Target	Value
TGF-βRI (ALK5) (Cell-free assay)	48 nM

在小鼠SMA-560和人SMA-560胶质瘤细胞中，SD-208抑制细胞生长，组成，和TGF-β诱发的迁移和浸润，并增强免疫原性。在体外，SD-208阻断TGF-β诱导的受体相关的Smads，Smad2和Smad3磷酸化，并刺激上皮细胞到间叶细胞的分化转化，迁移，以及侵袭到基底膜。在体外，SD-208也会废除TGF-β对新生内膜平滑肌样细胞(SMLC)增殖和迁移的保护作用。

SD-208 (1 mg/mL, p.o.)显著延长负荷SMA-560胶质瘤小鼠的中值存活率。在同源129S1小鼠体内，SD-208 (60 mg/kg/d, p.o.)抑制初级R3T肿瘤生长，并减少肺转移的数量和大小。在小鼠大动脉同种移植模型中，SD-208有效减少移植动脉硬化(TA)内膜增生的形成。